CareDx, Inc (CDNA)
NASDAQ$18.71-0.56 (-2.91%)
Market Cap
$1.07B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
509 of 924
Rank in Industry
26 of 49
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CDNA Insider Trading Activity
CDNA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $5,107,844 | 10 | 100 |
Related Transactions
| Novack Jeffrey Adam | Secretary and General Counsel | 0 | $0 | 4 | $281,500 | $-281,500 |
| Bickerstaff George | director | 0 | $0 | 1 | $367,102 | $-367,102 |
| Maag Peter | director | 0 | $0 | 2 | $1.3M | $-1.3M |
| Johnson Alexander L | See Remarks | 0 | $0 | 3 | $3.16M | $-3.16M |
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing …
Insider Activity of CareDx, Inc
Over the last 12 months, insiders at CareDx, Inc have bought $0 and sold $5.11M worth of CareDx, Inc stock.
On average, over the past 5 years, insiders at CareDx, Inc have bought $240,266 and sold $20.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $211,694 was made by Dhingra Ankur (Chief Financial Officer) on 2021‑11‑24.
List of Insider Buy and Sell Transactions, CareDx, Inc
| 2025-03-10 | Sale | Bickerstaff George | director | 20,000 0.0366% | $18.36 | $367,102 | +4.48% | |
| 2025-02-04 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 3,512 0.0065% | $23.30 | $81,829 | -6.56% | |
| 2024-12-04 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 1,917 0.0036% | $26.00 | $49,842 | -12.98% | |
| 2024-11-26 | Sale | Maag Peter | director | 5,000 0.0093% | $25.00 | $125,000 | -9.63% | |
| 2024-11-25 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 1,223 0.0023% | $24.00 | $29,352 | -5.85% | |
| 2024-11-18 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 5,534 0.0104% | $21.77 | $120,477 | +5.29% | |
| 2024-08-21 | Sale | Johnson Alexander L | See Remarks | 21,557 0.0399% | $32.58 | $702,327 | -30.04% | |
| 2024-08-20 | Sale | Maag Peter | director | 35,552 0.0686% | $33.04 | $1.17M | -28.07% | |
| 2024-08-20 | Sale | Johnson Alexander L | See Remarks | 39,466 0.0765% | $33.17 | $1.31M | -28.07% | |
| 2024-08-19 | Sale | Johnson Alexander L | See Remarks | 34,231 0.0641% | $33.55 | $1.15M | -31.33% | |
| 2023-10-02 | Sale | Seeto Reginald | See Remarks | 2,818 0.0052% | $6.91 | $19,483 | +58.67% | |
| 2023-09-05 | Sale | Seeto Reginald | See Remarks | 2,819 0.0054% | $9.49 | $26,762 | +8.86% | |
| 2023-08-14 | Sale | Seeto Reginald | See Remarks | 576 0.001% | $8.89 | $5,123 | +4.65% | |
| 2023-08-02 | Sale | Seeto Reginald | See Remarks | 2,819 0.0053% | $11.35 | $31,988 | -13.59% | |
| 2023-07-13 | Sale | Seeto Reginald | See Remarks | 5,260 0.01% | $10.33 | $54,357 | -3.76% | |
| 2023-07-13 | Sale | Maag Peter | director | 5,000 0.0095% | $10.34 | $51,681 | -3.76% | |
| 2023-07-03 | Sale | Seeto Reginald | See Remarks | 2,818 0.0052% | $8.48 | $23,901 | +14.49% | |
| 2023-06-28 | Sale | Seeto Reginald | See Remarks | 14,268 0.0266% | $8.76 | $125,016 | +10.55% | |
| 2023-06-28 | Sale | Maag Peter | director | 2,432 0.0045% | $8.72 | $21,216 | +10.55% | |
| 2023-06-02 | Sale | Seeto Reginald | See Remarks | 2,819 0.0053% | $8.13 | $22,911 | +14.73% |
Total: 224
*Gray background shows transactions not older than one year
Insider Historical Profitability
58.32%
| Maag Peter | director | 330024 0.5954% | $6.36M | 4 | 55 | +57.09% |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 1075090 1.9397% | $20.72M | 1 | 0 | <0.0001% |
| BYERS BROOK H | 751174 1.3553% | $14.48M | 1 | 0 | <0.0001% | |
| KLEINER PERKINS CAUFIELD & BYERS X A LP | 10 percent owner | 751174 1.3553% | $14.48M | 1 | 0 | <0.0001% |
| Gagnon Neil | 10 percent owner | 107940 0.1947% | $2.08M | 48 | 1 | +71.45% |
*Gray background shows insiders who have made transactions during last year
CDNA Institutional Investors: Active Positions
| Increased Positions | 130 | +59.36% | 8M | +16.44% |
| Decreased Positions | 95 | -43.38% | 7M | -13.66% |
| New Positions | 41 | New | 3M | New |
| Sold Out Positions | 42 | Sold Out | 1M | Sold Out |
| Total Postitions | 254 | +15.98% | 53M | +2.78% |
CDNA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $96,121.00 | 9.25% | 5.09M | -217,155 | -4.09% | 2024-12-31 |
| Vanguard Group Inc | $91,849.00 | 8.84% | 4.86M | +323,554 | +7.13% | 2024-12-31 |
| State Street Corp | $50,257.00 | 4.84% | 2.66M | +623,010 | +30.6% | 2024-12-31 |
| Ark Investment Management Llc | $45,532.00 | 4.38% | 2.41M | -579,497 | -19.39% | 2024-12-31 |
| Bamco Inc /Ny/ | $41,718.00 | 4.01% | 2.21M | +330,627 | +17.62% | 2024-12-31 |
| Fred Alger Management, Llc | $30,504.00 | 2.94% | 1.61M | +110,471 | +7.35% | 2024-12-31 |
| Invesco Ltd. | $28,631.00 | 2.75% | 1.51M | +51,160 | +3.5% | 2024-12-31 |
| Sumitomo Mitsui Trust Group, Inc. | $28,313.00 | 2.72% | 1.5M | -155,909 | -9.43% | 2024-12-31 |
| Nikko Asset Management Americas, Inc. | $28,313.00 | 2.72% | 1.5M | -154,741 | -9.36% | 2024-12-31 |
| Renaissance Technologies Llc | $27,069.00 | 2.6% | 1.43M | +196,298 | +15.88% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.